Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:58:29.269Z.
Calculation as of: 2026-10-06T18:58:29.269Z.
Quote observation: 2026-10-06T18:55:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9e5af3e3eb74887b0741ac42ed15d75d820cdffcd327c1f2ecbbd665592eb47e
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2014-06-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$353.41M
PS Ratio
11.05
TTM Avg
35.92
3Y Avg
58.08
5Y Avg
171.51
Market Cap
$356.36M
PS Ratio
5.46
TTM Avg
5.21
3Y Avg
3.68
5Y Avg
6.70
Market Cap
$359.18M
PS Ratio
6.07
TTM Avg
6.19
3Y Avg
8.23
5Y Avg
116.26
Market Cap
$357.88M
PS Ratio
N/A
TTM Avg
73.59
3Y Avg
73.59
5Y Avg
73.59
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | $348.23M | N/A | N/A | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $352.39M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $353.41M | 11.05 | 35.92 | 58.08 | 171.51 |
| Ocugen, Inc. (OCGN)vs › | $357.76M | 78.11 | 97.42 | 62.47 | 82.92 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $356.36M | 5.46 | 5.21 | 3.68 | 6.70 |
| Viemed Healthcare, Inc. (VMD)vs › | $357.26M | 1.18 | 1.31 | 1.47 | 1.73 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.18M | 6.07 | 6.19 | 8.23 | 116.26 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $357.88M | N/A | 73.59 | 73.59 | 73.59 |
| Embecta Corp. (EMBC)vs › | $357.66M | 0.35 | 0.45 | 0.65 | 0.90 |
| Opus Genetics, Inc. (IRD)vs › | $366.18M | 37.15 | 117.36 | 59.63 | 59.63 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-19 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2014-06-30 | 72015.16 |
| 2014-06-27 | 108022.74 |
| 2014-06-26 | 108022.74 |
| 2014-06-25 | 108022.74 |
| 2014-06-24 | 108022.74 |
| 2014-06-23 | 108022.74 |
| 2014-06-20 | 108022.74 |
